Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESSO 45 | Evidence-based, personalized approach preferred over single melanoma guidelines

Joanna Amkreutz, MD, PhD, Leiden University Medical Center, Leiden, Netherlands, advocates against establishing a single main re-excision guideline for melanoma care, instead emphasizing the need for introspective evaluation of re-excision practices based on the principle that more treatment does not necessarily equate to better outcomes. Data from the NORMA trials will inform clinical decision-making, with the goal of advancing toward less invasive melanoma treatment approaches. This interview took place at the 2026 European Society of Surgical Oncology (ESSO) Annual Meeting in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

I think there shouldn’t be one that is the main guideline. I think, as I mentioned before, that we really need to look inward. We into the role of re-excision in melanoma care because we believe that more treatment isn’t necessarily the same as better treatment. And I think that prospective studies that are ongoing right now, such as the Wiser-White study or the NORMA study or the MELMR trial, that we need to await those evidence originating from those trials...

I think there shouldn’t be one that is the main guideline. I think, as I mentioned before, that we really need to look inward. We into the role of re-excision in melanoma care because we believe that more treatment isn’t necessarily the same as better treatment. And I think that prospective studies that are ongoing right now, such as the Wiser-White study or the NORMA study or the MELMR trial, that we need to await those evidence originating from those trials. And that we can move to melanoma that is less invasive and more evidence-based and also more personalised. I think that is the main goal.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.